In our study, all participants underwent standardized cognitive screening at enrollment, and those with ad were excluded; therefore, higher CCL13 likely reflects sarcopenia‐related inflammatory activity rather than ad‐driven effects, supporting the inclusion of CCL13 within a multi‐marker panel for sarcopenia. This evidence concerns the gene CCL13 and sarcopenia.